| Autor: |
Michael P. Diamond, Susan A. McDonald, Jeanne E. Ballard, Roger Cady, Frederick J. Derosier, Deborah P. Dorner, Merle L. Diamond, Michelle E. Lener, Jonathan White, M. Chris Runken |
| Rok vydání: |
2011 |
| Předmět: |
|
| Zdroj: |
Headache: The Journal of Head and Face Pain. 51:664-673 |
| ISSN: |
0017-8748 |
| DOI: |
10.1111/j.1526-4610.2011.01894.x |
| Popis: |
(Headache 2011;51:664-673) Objective.— To evaluate the impact of a sumatriptan/naproxen sodium combination tablet on patient satisfaction, productivity, and functional disability in menstrual migraine treated during the mild pain phase of a single menstrual migraine attack associated with dysmenorrhea. Background.— Menstrual migraineurs with dysmenorrhea represent a unique patient population not previously studied. When health outcomes end points are analyzed alongside traditional efficacy end points in migraine studies, a more comprehensive and robust understanding of the many factors that may influence patients' choice of and adherence to pharmacological treatments for migraine is observed. Methods.— In 2 replicate, multicenter, randomized, double-blind, placebo-controlled trials, participants with menstrual migraine and dysmenorrhea treated a single menstrual migraine attack with a single fixed-dose tablet of sumatriptan 85 mg formulated with RT Technology™ and naproxen sodium 500 mg (sumatriptan–naproxen sodium) or placebo. Results.— Participants randomized to sumatriptan–naproxen sodium were significantly more satisfied than those randomized to placebo at 24 hours post dose, as demonstrated by higher satisfaction subscale scores for efficacy (P |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Plný text